This product is prepared for professional research settings that require reliable, high-quality peptide materials
Discuss your current medications with your nurse during intake so the right approach can be confirmed for your specific situation
SLU-PP-332 is a novel synthetic pan-agonist of the estrogen-related receptors (ERR, ERR, ERR), originally developed at Saint Louis University and characterised in recent pre-clinical literature as an exercise mimetic. It is widely studied in research models exploring mitochondrial biogenesis, fatty-acid oxidation, and metabolic endurance
According to ProHealth's cited reference (Sost MM et al., Nutrients, 2021), MicrobiomeX has been studied in clinical settings for its effect on shifting the gut microbiome toward butyrate-producing bacterial populations
Reductions in this ratio correlate strongly with cardiovascular risk reduction and metabolic improvement
Parenteral preparations with benzyl alcohol should not be used for fluid replacement